Peptides for Tendon and ligament injury in Dogs
The short answer
For tendon and ligament injury in dogs, the compounds under investigation are BPC-157, TB-500, MGF — of which BPC-157 has the strongest evidence base, graded emerging. Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs. No compound described here is FDA-approved for this use in dogs, and none should be started without veterinary involvement.
About the condition
Tendon and ligament tissue has a poor blood supply, which is the reason these injuries heal slowly and recur so readily. Repair tissue is also mechanically inferior to the original, so an inadequately rehabilitated injury tends to become a chronic one. This is where the largest share of the preclinical peptide literature sits — BPC-157's tendon-to-bone healing work and TB-500's cell migration research both target exactly this problem. It remains preclinical, but it is the most mechanistically coherent application on this site.
Compounds investigated for this condition
Ranked by strength of the published evidence.
The only peptide on this site with published canine pharmacokinetic data.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Full BPC-157 profile, dosing and safety →The most established compound in veterinary research, with equine work dating to the early 2000s.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Full TB-500 profile, dosing and safety →A locally acting muscle-repair peptide injected near the site of injury.
MGF is a splice variant of the IGF-1 gene that muscle produces in response to mechanical loading and damage. Its half-life is extremely short — around fifteen minutes — which means it acts where it is placed. That is why protocols call for injecting close to the injured muscle rather than anywhere convenient.
Full MGF profile, dosing and safety →Critical safety notes
These apply to the compounds listed above and should be read before considering any of them.
⚠ TB-500: Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
⚠ MGF: Contraindicated with active cancer
As an IGF-1 family growth factor, MGF promotes cell proliferation. It should not be used in a dog with known or suspected malignancy.
Breeds with elevated predisposition
Breed affects both the likelihood of this condition and, in some cases, which compounds are safe.
Common questions
What peptides are used for tendon and ligament injury in dogs?+
BPC-157, TB-500, MGF are the compounds investigated for tendon and ligament injury in dogs. BPC-157 carries the strongest evidence of these, graded as emerging evidence. None are FDA-approved for this use in dogs.
Do peptides actually help tendon and ligament injury in dogs?+
The honest answer is that the canine evidence is limited. Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs. The compounds investigated here have mechanistic support and, in some cases, published animal data — but controlled clinical trials in dogs with tendon and ligament injury have not been conducted. Any use is investigational and belongs in a conversation with your veterinarian rather than a decision made independently.
Which breeds are most affected by tendon and ligament injury?+
Border Collie, Australian Shepherd, German Shepherd, Labrador Retriever carry elevated predisposition to tendon and ligament injury. Breed matters beyond risk of the condition itself — some breeds carry genetic traits that change which compounds are safe, such as the MDR1 mutation in herding breeds and copper storage disease in Bedlington Terriers and certain Labrador lines.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
- 11.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.